Teva's product is an alternative to the brand product. As the first company to file an abbreviated new drug application containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity in the US.
Teva is distributing the product, under a licensing agreement entered into between Teva's subsidiary Barr Pharmaceuticals and Sanofi-Aventis US. Allegra-D is a registered trademark of Sanofi-Aventis US.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index